DK2197878T3 - Sammensætninger af kinaseinhibitorer og anvendelse heraf til behandling af cancer og andre sygdomme relateret til kinaser - Google Patents

Sammensætninger af kinaseinhibitorer og anvendelse heraf til behandling af cancer og andre sygdomme relateret til kinaser Download PDF

Info

Publication number
DK2197878T3
DK2197878T3 DK08829600.9T DK08829600T DK2197878T3 DK 2197878 T3 DK2197878 T3 DK 2197878T3 DK 08829600 T DK08829600 T DK 08829600T DK 2197878 T3 DK2197878 T3 DK 2197878T3
Authority
DK
Denmark
Prior art keywords
substituted
alkyl
heterocycle
aryl
cycloalkyl
Prior art date
Application number
DK08829600.9T
Other languages
English (en)
Inventor
Chiang Jia Li
Ji-Feng Liu
Youzhi Li
Harry Rogoff
Wei Li
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Application granted granted Critical
Publication of DK2197878T3 publication Critical patent/DK2197878T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)

Claims (8)

1. Forbindelse udvalat fra arunDen heståfinde af:
og en enantiomer, diastereomer, tautomer eller farmaceutisk acceptabelt Salt βΙΙθΓ solvat deraf.
2. Forbindelse ifølge krav 1, hvor forbindelsen er
eller en enantiomer, diastereomer, tautomer eller farmaceutisk acceptabelt salt eller solvat deraf.
3. Forbindelse udvalgt fra gruppen bestående af:
og en enantiomer, diastereomer, tautomer eller farmaceutisk acceptabelt salt eller solvat deraf.
4. Farmaceutisk sammensætning, der omfatter en forbindelse ifølge et hvilket som helst af kravene 1, 2 eller 3 og et farmaceutisk-acceptabelt excipiens, bærer eller fortyndingsmiddel.
5. Farmaceutisk sammensætning ifølge krav 4, hvor det farmaceutisk acceptable excipiens, bærer eller fortyndingsmiddel er en opløsningsblanding eller en suspensionsblanding, der omfatter, i vægt, omkring 12,5 % af dimethylacetamid, omkring 52,5 % PEG400, og omkring 35 % af 20 % Vitamin E.
6. Farmaceutisk sammensætning ifølge krav 4, der endvidere omfatter mindst ét andet middel til anti-cancerterapi.
7. Farmaceutisk sammensætning ifølge krav 6, hvor midlet til anti-cancerterapi er mindst ét middel udvalgt fra gruppen bestående af radioterapi (XRT)-midler, cytotoksiske midler, målmidler og hjælpemidler.
8. Farmaceutisk sammensætning ifølge krav 6 eller 7, hvor midlet til anticancerterapi er udvalgt fra gruppen bestående af gemcitabin, erlotinib, paclitaxel, docetaxel carboplatin, cisplatin, 5-fluoruracil, doxorubicin, sorafenib, imatinib, bevacizumab, cetuximab og trastuzumab.
DK08829600.9T 2007-09-06 2008-09-05 Sammensætninger af kinaseinhibitorer og anvendelse heraf til behandling af cancer og andre sygdomme relateret til kinaser DK2197878T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97041007P 2007-09-06 2007-09-06
US1338907P 2007-12-13 2007-12-13
US7429508P 2008-06-20 2008-06-20
PCT/US2008/075418 WO2009033033A2 (en) 2007-09-06 2008-09-05 Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases

Publications (1)

Publication Number Publication Date
DK2197878T3 true DK2197878T3 (da) 2016-11-14

Family

ID=40429714

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08829600.9T DK2197878T3 (da) 2007-09-06 2008-09-05 Sammensætninger af kinaseinhibitorer og anvendelse heraf til behandling af cancer og andre sygdomme relateret til kinaser

Country Status (16)

Country Link
US (5) US8299106B2 (da)
EP (2) EP3037419B1 (da)
JP (5) JP5452490B2 (da)
CN (1) CN101848908B (da)
CA (1) CA2736177A1 (da)
CY (1) CY1118012T1 (da)
DK (1) DK2197878T3 (da)
ES (2) ES2759347T3 (da)
HK (2) HK1148529A1 (da)
HR (1) HRP20161114T1 (da)
HU (1) HUE030774T2 (da)
LT (1) LT2197878T (da)
PL (1) PL2197878T3 (da)
PT (1) PT2197878T (da)
SI (1) SI2197878T1 (da)
WO (1) WO2009033033A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2197878T3 (da) * 2007-09-06 2016-11-14 Boston Biomedical Inc Sammensætninger af kinaseinhibitorer og anvendelse heraf til behandling af cancer og andre sygdomme relateret til kinaser
TWI543559B (zh) * 2007-12-10 2016-07-21 內數位專利控股公司 無線電鏈路控制封包丟棄及無線電鏈路控制重建觸發方法及裝置
AU2012222812A1 (en) 2011-02-28 2013-05-02 Mcmaster University Treatment of cancer with dopamine receptor antagonists
WO2014030001A1 (en) * 2012-08-23 2014-02-27 The Institute Of Cancer Research: Royal Cancer Hospital Fused heterocyclic compounds and their use
AU2014243869A1 (en) * 2013-03-13 2015-09-24 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
JP2016521761A (ja) * 2013-06-20 2016-07-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｍｐｋ活性を有するオレフィン置換オキシインドール
EP3099297A4 (en) * 2014-01-27 2017-06-07 Boston Biomedical, Inc. Novel methods for treating cancer
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EA201792320A1 (ru) * 2015-04-27 2018-02-28 Бостон Биомедикал, Инк. Способ лечения рака ингибитором пути stat3 и ингибитором киназы
JPWO2017026119A1 (ja) * 2015-08-10 2018-05-24 大日本住友製薬株式会社 ５−（チアゾール−４−イル）インドリン−２−オン誘導体の精製方法
WO2017160978A1 (en) 2016-03-15 2017-09-21 Boston Biomedical, Inc. Cell cultures and use thereof
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
AU2019345297A1 (en) * 2018-09-18 2021-04-29 1 Globe Biomedical Co., Ltd. Treatment for non-alcoholic fatty liver disease
JP2022501435A (ja) * 2018-09-18 2022-01-06 １グローブ バイオメディカル カンパニー， リミテッド 肥満に対する処置
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2829451B2 (ja) * 1990-11-30 1998-11-25 大塚製薬株式会社 活性酸素抑制剤
CA2264220A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999015524A1 (en) * 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
CA2399358C (en) * 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
ES2243461T3 (es) * 2000-02-28 2005-12-01 Sugen, Inc. Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa.
US6706709B2 (en) * 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
JP4343534B2 (ja) * 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト ３ハイブリッド・アッセイ・システム
WO2002081466A1 (en) * 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20050032871A1 (en) * 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
US7105563B2 (en) * 2003-10-24 2006-09-12 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
MX2008009557A (es) 2006-01-27 2009-01-07 Shanghai Hengrui Pharm Co Ltd Inhibidores de la cinasa de proteina de la pirrolo [3,2-c] piridin-4-ona-2-indolinona.
JP5220848B2 (ja) * 2007-06-01 2013-06-26 エフ．ホフマン−ラ ロシュ アーゲー ピペリジンアミド誘導体
DK2197878T3 (da) * 2007-09-06 2016-11-14 Boston Biomedical Inc Sammensætninger af kinaseinhibitorer og anvendelse heraf til behandling af cancer og andre sygdomme relateret til kinaser
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof

Also Published As

Publication number Publication date
CA2736177A1 (en) 2009-03-12
CN101848908A (zh) 2010-09-29
JP5701372B2 (ja) 2015-04-15
JP2010538091A (ja) 2010-12-09
WO2009033033A2 (en) 2009-03-12
EP2197878B1 (en) 2016-08-17
CY1118012T1 (el) 2017-05-17
JP5452490B2 (ja) 2014-03-26
HK1226071A1 (zh) 2017-09-22
HK1148529A1 (en) 2011-09-09
PL2197878T3 (pl) 2017-01-31
CN101848908B (zh) 2014-07-02
JP2015129152A (ja) 2015-07-16
PT2197878T (pt) 2016-11-04
HUE030774T2 (hu) 2017-05-29
US20180022743A1 (en) 2018-01-25
EP2197878A4 (en) 2012-02-08
SI2197878T1 (sl) 2016-10-28
US9725444B2 (en) 2017-08-08
US20100285006A1 (en) 2010-11-11
ES2591028T3 (es) 2016-11-24
JP5974124B2 (ja) 2016-08-23
EP3037419A1 (en) 2016-06-29
WO2009033033A3 (en) 2009-04-30
US20120321622A1 (en) 2012-12-20
EP3037419B1 (en) 2019-09-04
US8299106B2 (en) 2012-10-30
EP2197878A2 (en) 2010-06-23
HRP20161114T1 (hr) 2016-11-04
JP2019070051A (ja) 2019-05-09
ES2759347T3 (es) 2020-05-08
JP6495868B2 (ja) 2019-04-03
LT2197878T (lt) 2016-09-26
JP2014058573A (ja) 2014-04-03
US20150197517A1 (en) 2015-07-16
US20190248781A1 (en) 2019-08-15
JP2016180013A (ja) 2016-10-13

Similar Documents

Publication Publication Date Title
DK2197878T3 (da) Sammensætninger af kinaseinhibitorer og anvendelse heraf til behandling af cancer og andre sygdomme relateret til kinaser
KR102281288B1 (ko) 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
CA2627623C (en) Methods for inhibiting protein kinases
KR101464060B1 (ko) 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
CN106922146B (zh) 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
KR20230019101A (ko) 벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도
US9187454B2 (en) Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN112867721A (zh) Sting激动性化合物
WO2014164767A1 (en) Novel compounds and compositions for inhibition of fasn
JP2016513656A5 (da)
JP2011510004A (ja) タンパク質キナーゼ阻害剤及びその使用
JP7109919B2 (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CN115043842A (zh) 胺基取代双环类抑制剂及其制备方法和应用
AU2010268019A1 (en) Substituted 2-carboxamide cycloamino ureas
CA3157778A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
CN105461709B (zh) 取代脲衍生物及其在药物中的应用
JP7478673B2 (ja) アデノシン受容体アンタゴニストとしてのピラゾロピリミジン化合物
CN117820305A (zh) 杂环取代喹唑啉及其制备方法和应用
CN114502553A (zh) 作为第iii型受体酪氨酸激酶抑制剂之杂环吡唑衍生物